Ben Kuiken
About Ben Kuiken
Ben Kuiken is the Director of Oncology Franchise Marketing at BMS, with extensive experience in pharmaceutical marketing and strategic planning.
Title and Current Company
Ben Kuiken holds the position of Director of Oncology Franchise Marketing at BMS. In this role, he is responsible for identifying operational redundancies across the Oncology franchise and achieving savings by leveraging synergies and consolidating business practices. Kuiken also drives US involvement in Global BMS Oncology's long-term strategic planning.
Education and Academic Background
Ben Kuiken attended Whitman College, where he studied Economics, French, and earned a Bachelor of Science degree in English. His diverse academic background has provided him with a solid foundation in various interdisciplinary fields, which he applies in his professional roles.
Professional Experience at Bristol-Myers Squibb
Ben Kuiken has held multiple roles at Bristol-Myers Squibb (BMS). As the Director of Payer Marketing, US Brand Team, from 2006 to 2009, he developed and executed US managed markets strategy and launch plans for Onglyza. Prior to this, he was the Director of Early Neuroscience Global Marketing from 2005 to 2006, where he developed global marketing strategies for BMS' neuroscience pipeline assets and provided commercial input to discovery and development teams.
Role at Genelabs Technologies
From 2000 to 2005, Ben Kuiken served as the Senior Director of Commercial Operations at Genelabs Technologies. He handled global manufacturing operations and corporate professional relations. Kuiken also managed the global commercialization strategy for Prestara, an investigational drug for lupus, and coordinated with North American commercial partner Watson Pharmaceuticals.
Experience at GlaxoSmithKline
Ben Kuiken worked at GlaxoSmithKline in various senior roles. As a Senior Product Manager in Zyban Marketing from 1995 to 1997, he developed US strategic direction for phase II/III compounds for pain, arthritis, insomnia, and Alzheimer’s. Before that, he was a Hospital/District Manager, managing three teams in Kansas City/Seattle from 1992 to 1997. Additionally, he was responsible for strategic business planning, life cycle management, business interactions with US Medical Affairs, and generic defense strategy for Wellbutrin.